Saleh Alahmed
Research Subjects
Research Interests
Saleh Alahmed has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Abdullah Kamal
Dallah Hospital, Riyadh, Saudi Arabia
1 shared publicationAfaf Alshammary
Ministry of National Guard (Health Affairs), King Abdulaziz Medical City, Riyadh and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publication- Ahmed Abdallah
Merck Serono Middle East FZ-Ltd, Jeddah, Saudi Arabia
1 shared publication Ahmed Elboghdady
Merck Serono Middle East FZ-Ltd, Jeddah, Saudi Arabia
1 shared publicationAshraf Amir
Family Medicine International Medical Center, Jeddah, Saudi Arabia
1 shared publicationHani Shalabi
University of Jeddah, Jeddah, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 16, 105-115
Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment
The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients’ individualised HbA1c goals and to minimise cardiovascular risk.
- 1 January 2023
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 16, 105-115
Open AccessAddressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment
The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients’ individualised HbA1c goals and to minimise cardiovascular risk.